The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ciamatil     10-(3-dimethylamino-2- methyl...

Synonyms: Cianatil, Tercian, Cyamemazin, Ciamemazina, Cyamemazine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Kyamepromazine

  • PATIENT: A woman who developed three episodes of drug-induced hepatitis within 3 years as a result of successive treatment with two tricyclic antidepressants, trimipramine and desipramine, and one neuroleptic derivative, cyamemazine [1].

Psychiatry related information on Kyamepromazine


High impact information on Kyamepromazine


Chemical compound and disease context of Kyamepromazine


Biological context of Kyamepromazine


Anatomical context of Kyamepromazine


Associations of Kyamepromazine with other chemical compounds


Gene context of Kyamepromazine


Analytical, diagnostic and therapeutic context of Kyamepromazine

  • The effective plasma level of the drug leading to 50% of receptor occupancy was estimated by fitting RO with plasma levels of cyamemazine at the time of the PET scan [6].
  • Rats prepared for microdialysis (striatum) were intraperitoneally given cyamemazine 1 mg/kg, 5 mg/kg or vehicle ( n=4 in each group) [14].
  • Cyamemazine was formally identified in postmortem blood using an HPLC-DAD screening procedure, and then quantified in some postmortem samples by means of a specific HPLC method [9].


  1. Cross hepatotoxicity between tricyclic antidepressants and phenothiazines. Remy, A.J., Larrey, D., Pageaux, G.P., Ribstein, J., Ramos, J., Michel, H. European journal of gastroenterology & hepatology. (1995) [Pubmed]
  2. Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in mice. Naassila, M., Legrand, E., d'Alche-Birée, F., Daoust, M. Psychopharmacology (Berl.) (1998) [Pubmed]
  3. 5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity. Alvarez-Guerra, M., d'Alché-Birée, F., Wolf, W.A., Vargas, F., Dib, M., Garay, R.P. Psychopharmacology (Berl.) (2000) [Pubmed]
  4. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Bourin, M., Nic Dhonnchadha BA, n.u.l.l., Claude Colombel, M., Dib, M., Hascoët, M. Behav. Brain Res. (2001) [Pubmed]
  5. Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome. Favre, J.D., Allain, H., Aubin, H.J., Frija-Orvoen, E., Gillet, C., Lejoyeux, M., Payen, A., Weber, M., Garcia-Acosta, S., Kermadi, I., Dib, M. Human psychopharmacology. (2005) [Pubmed]
  6. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian). Hodé, Y., Reimold, M., Demazières, A., Reischl, G., Bayle, F., Nuss, P., Hameg, A., Dib, M., Macher, J.P. Psychopharmacology (Berl.) (2005) [Pubmed]
  7. Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Hameg, A., Bayle, F., Nuss, P., Dupuis, P., Garay, R.P., Dib, M. Biochem. Pharmacol. (2003) [Pubmed]
  8. Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs. Crumb, W., Llorca, P.M., Lancon, C., Thomas, G.P., Garay, R.P., Hameg, A. Eur. J. Pharmacol. (2006) [Pubmed]
  9. Toxicological data in a fatality involving cyamemazine. Tracqui, A., Kintz, P., Jamey, C., Mangin, P. Journal of analytical toxicology. (1993) [Pubmed]
  10. Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. Bourin, M., Dailly, E., Hascöet, M. CNS drug reviews. (2004) [Pubmed]
  11. Contrasting action of flavonoids on phototoxic effects induced in human skin fibroblasts by UVA alone or UVA plus cyamemazine, a phototoxic neuroleptic. Filipe, P., Silva, J.N., Haigle, J., Freitas, J.P., Fernandes, A., Santus, R., Morlière, P. Photochem. Photobiol. Sci. (2005) [Pubmed]
  12. 5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle. Alvarez-Guerra, M., Hameg, A., Bayle, F., Dib, M., Garay, R.P. Eur. J. Pharmacol. (2002) [Pubmed]
  13. An insight into the mechanisms of the phototoxic response induced by cyamemazine in cultured fibroblasts and keratinocytes. Morlière, P., Haigle, J., Aissani, K., Filipe, P., Silva, J.N., Santus, R. Photochem. Photobiol. (2004) [Pubmed]
  14. Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine. Peinado, J., Hameg, A., Garay, R.P., Bayle, F., Nuss, P., Dib, M. Naunyn Schmiedebergs Arch. Pharmacol. (2003) [Pubmed]
WikiGenes - Universities